4.1.3 Neuron loss in 5XFAD mice correlates with the presence of intraneuronal Aβ 4.1.4 Spatial working memory impairment in the 5XFAD mouse model 4.1.5 Reduced anxiety in 5XFAD mice 4.1.6 Plaque pathology and pyroglutamate-modified Aβ in 5XFAD mice 4.1.7 Conclusions of project I 4.2 Project II: "Evaluating the role of glutaminyl cyclase and pyroglutamate-modified Aβ in AD via the 5XFAD/hQC and 5XFAD/QC-KO mouse models" 4.2.1 The 5XFAD/hQC mouse model 4.2.1.1 hQC overexpression alters pyroglutamate-modified Aβ levels and plaque pathology 4.2.1.2 hQC overexpression worsens the behavior impairments of 5XFAD mice 4.2.2 The 5XFAD/QC-KO mouse model 4.2.2.1 Glutaminyl cyclase ablation reduces Aβ concentration and plaque pathology in 5XFAD mice 4.2.2.2 Glutaminyl cyclase knock-out rescues the spatial working memory impairment in 5XFAD mice 4.2.3 Conclusions of project II 5. Summary 6. References 7. Curriculum Vitae 8. List of Publications List of Abbreviations 5XFAD Five familial AD mutations AD Alzheimer's disease ADAM A disintegrin and metalloproteinase AICD APP intracellular domain APH-1 Anterior pharynx-defective-1 APLP Amyloid precursor like protein APOE Apolipoprotein E APP Amyloid precursor protein Aβ Amyloid beta Aβ 1-x Aβ of variable C-terminal lengths, starting with unmodified N-terminalAβ pE11-x Aβ of variable C-terminal lengths, starting with pyroglutamate at the eleventh position Aβ pE3-x Aβ of variable C-terminal lengths, starting with pyroglutamate at the third position Aβ (E)11-x Aβ truncated at the eleventh position, starting with glutamate Aβ (E)3-x Aβ truncated at the third position, starting with glutamate Aβ (Q)3-x Aβ truncated at the third position, starting with glutamine Aβ x-40